Correction to Cost of Covid-19 Drug Remdesivir Article
June 29 2020 - 1:34PM
Dow Jones News
Gilead Sciences Inc. will charge a lower price of $390 a dose of
remdesivir to some U.S. government agencies that directly purchase
pharmaceuticals, such as the Department of Veterans Affairs.
"Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient on
Private Insurance, " at 7 a.m. and 10:41 a.m., incorrectly said the
lower price would be extended to government health programs such as
Medicare.
(END) Dow Jones Newswires
June 29, 2020 13:19 ET (17:19 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2024 to May 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2023 to May 2024